Showing results (141-150 of 232) with videos related to
Sort By:
Pageof 24
Endoscopy International Open|November 29, 2024
Dye-based chromoendoscopy versus i-scan virtual chromoendoscopy in long-standing ulcerative colitis: Multicenter prospective RCTAlexander Jans, Pieter Sinonquel, Tom C J Seerden, et al.Gastroenterology|March 31, 2018
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's DiseaseSilvio Danese, Stefanos Bonovas, Anthony Lopez, et al.United European Gastroenterology Journal|May 19, 2018
Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonistsMartine De Vos, Barbara Dhooghe, Severine Vermeire, et al.Inflammatory Bowel Diseases|November 1, 2011
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus reportBrian G Feagan, Marc Lémann, Ragnar Befrits, et al.The Lancet. Gastroenterology & Hepatology|September 8, 2022
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extensionSeverine Vermeire, Bruce E Sands, Herbert Tilg, et al.Journal of Crohn'S & Colitis|January 29, 2016
Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn's DiseaseKarin Amcoff, Marie Joossens, Marie J Pierik, et al.Inflammatory Bowel Diseases|January 9, 2007
The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patientsLene Riis, Ida Vind, Severine Vermeire, et al.Gastroenterology|July 10, 2002
NOD2/CARD15 does not influence response to infliximab in Crohn's diseaseSeverine Vermeire, Edouard Louis, Paul Rutgeerts, et al.Journal of Crohn'S & Colitis|May 26, 2025
Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b studySeverine Vermeire, Josianne Nitcheu, Paul Gineste, et al.Gastroenterology|November 26, 2018
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative ColitisWilliam J Sandborn, Marcoli Cyrille, Mark Berner Hansen, et al.Pageof 24